China NT Pharma Group Company Limited (1011.HK)
HKD 0.27
(1.89%)
HKD 0.27
(1.89%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -143.59 Million CNY | -116.23% |
| 2022 | -66.4 Million CNY | 56.12% |
| 2021 | -151.33 Million CNY | 20.88% |
| 2020 | -191.26 Million CNY | 67.76% |
| 2019 | -593.2 Million CNY | 38.06% |
| 2018 | -957.66 Million CNY | -679.72% |
| 2017 | 165.19 Million CNY | 42.19% |
| 2016 | 116.18 Million CNY | 32.48% |
| 2015 | 87.69 Million CNY | 4101.92% |
| 2014 | 2.08 Million CNY | 100.31% |
| 2013 | -673.45 Million CNY | 39.29% |
| 2012 | -1.1 Billion CNY | -573.3% |
| 2011 | 234.37 Million CNY | 82.24% |
| 2010 | 128.61 Million CNY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 661 Thousand CNY | 0.0% |
| 2023 Q2 | -5.61 Million CNY | 0.0% |
| 2023 FY | -143.59 Million CNY | -116.23% |
| 2022 Q4 | -38.16 Million CNY | 0.0% |
| 2022 Q2 | -28.23 Million CNY | 0.0% |
| 2022 FY | -66.4 Million CNY | 56.12% |
| 2021 FY | -151.33 Million CNY | 20.88% |
| 2021 Q4 | -146.88 Million CNY | 0.0% |
| 2021 Q2 | -2.65 Million CNY | 0.0% |
| 2020 Q2 | -46.74 Million CNY | 0.0% |
| 2020 FY | -191.26 Million CNY | 67.76% |
| 2019 FY | -593.2 Million CNY | 38.06% |
| 2019 Q2 | -43.42 Million CNY | 0.0% |
| 2018 FY | -957.66 Million CNY | -679.72% |
| 2018 Q4 | - CNY | 0.0% |
| 2018 Q2 | 104.5 Million CNY | 0.0% |
| 2017 Q2 | 102.88 Million CNY | 0.0% |
| 2017 Q4 | - CNY | 0.0% |
| 2017 FY | 165.19 Million CNY | 42.19% |
| 2016 Q2 | 50.06 Million CNY | 0.0% |
| 2016 Q4 | - CNY | 0.0% |
| 2016 FY | 116.18 Million CNY | 32.48% |
| 2015 FY | 87.69 Million CNY | 4101.92% |
| 2015 Q2 | 36.49 Million CNY | 0.0% |
| 2015 Q4 | 51.2 Million CNY | 0.0% |
| 2014 Q4 | -207 Thousand CNY | 0.0% |
| 2014 FY | 2.08 Million CNY | 100.31% |
| 2014 Q2 | 2.29 Million CNY | 0.0% |
| 2013 Q4 | -241.37 Million CNY | 0.0% |
| 2013 FY | -673.45 Million CNY | 39.29% |
| 2013 Q2 | -432.08 Million CNY | 0.0% |
| 2012 Q2 | - CNY | 0.0% |
| 2012 FY | -1.1 Billion CNY | -573.3% |
| 2012 Q4 | - CNY | 0.0% |
| 2011 FY | 234.37 Million CNY | 82.24% |
| 2011 Q4 | - CNY | 0.0% |
| 2011 Q2 | - CNY | 0.0% |
| 2010 FY | 128.61 Million CNY | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 105.03 Million HKD | 236.702% |
| Grand Pharmaceutical Group Limited | 1.87 Billion HKD | 107.638% |
| Extrawell Pharmaceutical Holdings Limited | -162.94 Million HKD | 11.88% |
| Wai Yuen Tong Medicine Holdings Limited | -15.35 Million HKD | -835.074% |
| Qianhai Health Holdings Limited | -52.7 Million HKD | -172.441% |
| Lee's Pharmaceutical Holdings Limited | 16.69 Million HKD | 959.923% |
| Essex Bio-Technology Limited | 275.25 Million HKD | 152.165% |
| Tongfang Kontafarma Holdings Limited | -28.84 Million HKD | -397.833% |
| PuraPharm Corporation Limited | -106.08 Million HKD | -35.359% |
| SSY Group Limited | 1.31 Billion HKD | 110.889% |
| JBM (Healthcare) Limited | 130.46 Million HKD | 210.062% |
| Jacobson Pharma Corporation Limited | 266.96 Million HKD | 153.785% |
| China Resources Pharmaceutical Group Limited | 3.85 Billion HKD | 103.726% |